Literature DB >> 28918088

Evaluation of Cerebrovascular Reactivity in Subjects with and without Obstructive Sleep Apnea.

Clodagh M Ryan1, Anne Battisti-Charbonney2, Olivia Sobczyk3, David J Mikulis4, James Duffin5, Joseph A Fisher6, Lashmi Venkatraghavan7.   

Abstract

BACKGROUND: Both obstructive sleep apnea (OSA) and altered cerebrovascular reactivity (CVR) are associated with increased stroke risk. Nevertheless, the incidence of abnormal CVR in patients with OSA is uncertain due to the high variability in the way CVR is measured both within and between studies. We hypothesized that a standardized CVR with a consistent vasoactive stimulus and cerebral blood flow (CBF) measure would be reduced in patients with severe OSA compared with healthy controls.
METHODS: This was a prospective study in which subjects with and without OSA were administered a standardized hypercapnic stimulus, and CBF was monitored by blood oxygen level-dependent magnetic resonance signal changes, a high space and time resolved surrogate for CBF.
RESULTS: Twenty-four subjects with OSA (mean age 45.9 years, apnea-hypopnea index [AHI] 26.8 per hour) and 6 control subjects (mean age 42.8 years, AHI 2.4 per hour) were included. Compared with controls, subjects with OSA had a significantly greater whole brain (.1565 versus .1094, P = .013), gray matter (.2077 versus .1423, P = .009), and white matter (.1109 versus .0768, P = .024) CVR, respectively.
CONCLUSIONS: Contrary to expectations, subjects with OSA had greater CVR compared with control subjects.
Copyright © 2018 National Stroke Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Obstructive sleep apnea; cerebral blood flow; cerebrovascular disease; cerebrovascular reactivity

Mesh:

Substances:

Year:  2017        PMID: 28918088     DOI: 10.1016/j.jstrokecerebrovasdis.2017.08.015

Source DB:  PubMed          Journal:  J Stroke Cerebrovasc Dis        ISSN: 1052-3057            Impact factor:   2.136


  7 in total

1.  MRI evaluation of cerebrovascular reactivity in obstructive sleep apnea.

Authors:  Pei-Hsin Wu; Ana E Rodríguez-Soto; Zachary B Rodgers; Erin K Englund; Andrew Wiemken; Michael C Langham; John A Detre; Richard J Schwab; Wensheng Guo; Felix W Wehrli
Journal:  J Cereb Blood Flow Metab       Date:  2019-07-15       Impact factor: 6.200

2.  Sleep and Stroke: New Updates on Epidemiology, Pathophysiology, Assessment, and Treatment.

Authors:  H Lee Lau; Tanja Rundek; Alberto R Ramos
Journal:  Curr Sleep Med Rep       Date:  2019-05-02

3.  Altered regional cerebral blood flow in obstructive sleep apnea is associated with sleep fragmentation and oxygen desaturation.

Authors:  Lirong Yan; Hea Ree Park; Eric J Kezirian; Soonhyun Yook; Jae-Hun Kim; Eun Yeon Joo; Hosung Kim
Journal:  J Cereb Blood Flow Metab       Date:  2021-04-28       Impact factor: 6.200

4.  Impact of mandibular advancement device therapy on cerebrovascular reactivity in patients with carotid atherosclerosis combined with OSAHS.

Authors:  Lu Qin; Na Li; Junyao Tong; Zeliang Hao; Lili Wang; Ying Zhao
Journal:  Sleep Breath       Date:  2021-01-07       Impact factor: 2.816

5.  Cerebrovascular Reactivity Measurement Using Magnetic Resonance Imaging: A Systematic Review.

Authors:  Emilie Sleight; Michael S Stringer; Ian Marshall; Joanna M Wardlaw; Michael J Thrippleton
Journal:  Front Physiol       Date:  2021-02-25       Impact factor: 4.566

6.  Abnormal Cerebrovascular Reactivity and Functional Connectivity Caused by White Matter Hyperintensity Contribute to Cognitive Decline.

Authors:  Dan Yang; Ruomeng Qin; Lan Chu; Hengheng Xu; Ling Ni; Junyi Ma; Pengfei Shao; Lili Huang; Bing Zhang; Meijuan Zhang; Yun Xu
Journal:  Front Neurosci       Date:  2022-03-04       Impact factor: 4.677

7.  Metoprolol prevents neuronal dendrite remodeling in a canine model of chronic obstructive sleep apnea.

Authors:  Lin Yang; Jing Zhao; Yang Qu; Qiang Sun; Ting-Ting Li; Mei-Ling Yan; Ming-Jing Duan; Ke-Xin Li; Yan-Ru Wang; Si-Yu Huang; Shuai Zhang; Yue Li; Jing Ai
Journal:  Acta Pharmacol Sin       Date:  2019-12-20       Impact factor: 6.150

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.